Association of inflammatory Chemokine gene CCL2I/D with Bladder cancer risk in North Indian population

Molecular Biology Reports

Volumn 39, Issue 10, 2012, Pages 9827-9834

  Singh, Vibha ^a   Srivastava, Priyanka ^a   Srivastava, Neena ^b   Kapoor, Rakesh ^a   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Bacillus calmette guerin; Bladder cancer; Chemokine gene polymorphism; Haplotype; Survival

Indexed keywords

CHEMOKINE RECEPTOR CCR2; MONOCYTE CHEMOTACTIC PROTEIN 1; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOKINE CCL2 GENE; CHEMOKINE RECEPTOR CCR2 GENE; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HAPLOTYPE; HIGH RISK POPULATION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INDEL MUTATION; INDIAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SMOKING; SURVIVAL TIME;

BCG VACCINE; CANCER VACCINES; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DISEASE-FREE SURVIVAL; EPISTASIS, GENETIC; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; INDIA; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION; RECEPTORS, CCR2; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

MYCOBACTERIUM BOVIS BCG;

EID: 84868534006     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1849-8     Document Type: Article

References (28)

1. Franekova M, Halasova E, Bukovska E, Luptak J, Dobrota D (2008) Gene polymorphisms in bladder cancer. Urol Oncol 26:1-8
2. Sinha R, Anderson DE, McDonald SS, Greenwald P (2003) Cancer risk and diet in India. J Postgrad Med 49:222-228
3. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239-249
4. Zlotnik A, Yoshie O, Nomiyama H (2006) The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7(12):243
5. Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in tumor growth. Cancer Lett 256:137-165
6. Lazennec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16(3):133-144
7. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231-237
8. Rovin BH, Lu L, Saxena R (1999) A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259:3448
9. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T (2004) A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS 18:729-738
10. Zhang J, Patel L, Pienta KJ (2010) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21:41-48
11. Colombel M, Soloway M, Akaza H et al (2008) Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol Suppl 7:618-626
12. Miller SA, Dykes DD, Polesky Hf (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215
13. Ahluwalia TS, Khullar M, Ahuja M, Kohli HS, Bhansali A, Mohan V, Venkatesan R, Rai TS, Sud K, Singal PK (2009) Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 4:51-68
14. Narter KF, Agachan B, Sozen S, Cincin ZB, Isbir T (2010) CCR2-64I is a risk factor for development of bladder cancer. Genet Mol Res 9:685-692
15. Takashi K, Hwang T (2006) Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 79:639-651
16. Chinoy H, Salway F, Fertig N, Tait BD, Oddis CV, Ollier WE, Cooper RG (2006) Monocyte chemotactic protein-1 single nucleotide polymorphisms do not confer susceptibility for the development of adult onset polymyositis/ dermatomyositis in UK Caucasians. Rheumatology (Oxford) 46:604-607
17. Valkovic T, Lucin K, Krstulja M (1998) Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194:335-340
18. Ueno T, Toi M, Saji H (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6:3282-3289
19. Kruszyna Ł, Lianeri M, Rubis ZB, Knuła H, Rybczynska M, Gazdecka GS, Jagodzinski PP (2011) CCL2 22518 A/G single nucleotide polymorphism as a risk factor for breast cancer. Mol Biol Rep 38:1263-1267
20. Vázquez-Lavista LG, Lima G, Gabilondo F, Llorente L (2009) Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology 74:414-418
21. Prasad P, Tiwari AK, Kumar KM, Ammini AC, Gupta A, Gupta R, Thelma BK (2007) Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med Genet 8:20
22. Singh R, Kapoor R, Srivastava A, Mittal RD (2009) Impact of chemokine receptor CCR2 and CCR5 gene polymorphism on allograft outcome in North Indian renal transplant recipients. Scand J Immunol 69:51-56
23. Katrancioglu N, Manduz S, Karahan O, Yilmaz MB, Sezgin I, Bagci G, Berkan O (2011) The role of the CCR2 gene polymorphism in abdominal aortic aneurysms. Angiology 62:140-143
24. Chatterjee K, Dandara C, Hoffman M, Williamson AL (2010) CCRr2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women. BMC Cancer 10:278
25. Mulherin SA, Brien TRO, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, Jamieson BD, Meyer L, Michael NL, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Theodorou ID, Vlahov D, Rosenberg PS (2003) International Meta-Analysis of HIV Host Genetics. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS 17:377-387
26. Miyagishi R, Niino M, Fukazawa T, Yabe I, Kikuchi S, Tashiro K (2003) C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 145:135-138
27. Coelho A, Matos A, Catarino R, Pinto D, Pereira D, Lopes C, Medeiros R (2005) Protective role of the polymorphism CCR2-64I in the progression from squamousintraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol 9:760-764
28. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA (2004) Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet 41:59